--- a
+++ b/clusters/3009knumclusters/clust_258.txt
@@ -0,0 +1,262 @@
+Have moderate or severe cardiovascular disease:
+Significant history of cardiovascular disease
+Patients with clinically relevant medical history, including autoimmune disease, cardiovascular disease, hepatic disease or bleeding disorders
+Uncontrolled or significant cardiovascular disease
+Evidence of clinically significant cardiovascular and respiratory conditions
+Significant cardiovascular disease;
+Significant cardiovascular disease or active pulmonary disease
+Cardiovascular Risks as outlined in the protocol.
+Clinically significant cardiovascular disease
+Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease, cardiovascular disease, and presence of an abnormal electrocardiogram (ECG)
+Patients with pre-existing history of or known cardiovascular risk
+Significant cardiovascular disease
+Significant cardiovascular disease
+Any of the following cardiovascular criteria:
+Subjects with clinically significant cardiovascular disease, including:
+Significant cardiovascular/cerebrovascular disease within 6 months prior to Day 1 of study drug administration
+Significant cardiovascular disease
+Has a history of or current uncontrolled cardiovascular disease
+History or evidence of cardiovascular risk
+Current severe, uncontrolled systemic disease (for example [e.g.] clinically significant cardiovascular, pulmonary, or metabolic disease)
+Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could interfere with per-protocol evaluations.
+Significant cardiovascular disease.
+Have moderate or severe cardiovascular disease.
+Episode of significant cardiovascular/cerebrovascular acute disease within 6 months prior to Cycle 1 Day 1
+Clinically significant cardiovascular disease
+Significant cardiovascular disease
+Any significant cardiovascular events within 6 months prior to study entry
+Clinically significant cardiovascular disease, history of myocardial infarction within the last 6 months, or evidence of QTc interval prolongation at screening
+History of a significant cardiovascular illness
+Significant active cardiovascular or pulmonary disease including:
+Significant cardiovascular disease
+Current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular, pulmonary, or renal disease) other than cancer
+Uncontrolled or significant cardiovascular diseases
+History or evidence of cardiovascular risk
+Uncontrolled or significant cardiovascular disease
+Subjects with significant or uncontrolled cardiovascular disease
+Significant cardiovascular disease
+Clinically significant cardiovascular disease or condition
+Patients with clinically significant cardiovascular disease, thromboembolic disease, or significant risk of bleeding.
+Uncontrolled or significant cardiovascular disease
+Significant cardiovascular disease or ECG abnormalities.
+Currently active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first dose
+Clinically significant cardiovascular or pulmonary disease
+History of uncontrolled cardiovascular disease including
+Significant known cardiovascular impairment.
+Uncontrolled or significant cardiovascular disease.
+History of clinically significant cardiovascular disease
+Clinically significant cardiovascular disease.
+Significant cardiovascular disease, within 3 months prior to randomisation, unstable arrhythmias, or unstable angina
+Clinically significant cardiovascular disease or condition
+Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)
+History of clinically significant cardiovascular disease;
+Uncontrolled or significant cardiovascular disease
+Any known uncontrolled cardiovascular disease;
+Clinically significant cardiovascular disease.
+Clinically significant cardiovascular disease
+Evidence of significant, uncontrolled, concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease
+Evidence of significant cardiovascular conditions as specified below:
+Uncontrolled or significant cardiovascular disease
+History of cardiovascular disease
+Cardiovascular disorders
+Significant active cardiovascular or pulmonary disease before administration of the first dose of study drug, including:
+Have moderate or severe cardiovascular disease.
+Patients with a significant cardiovascular disease or condition, including:
+Have moderate or severe cardiovascular disease.
+Have moderate or severe cardiovascular disease:
+Patients with a significant cardiovascular disease or condition, including:
+Clinically significant cardiovascular disease.
+Medically significant cardiac event or unstable cardiovascular function defined as:
+Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
+Clinically significant cardiovascular disease
+Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, or congestive heart failure
+Clinically significant cardiovascular disease including:
+Have significant, uncontrolled, or active cardiovascular disease, including, but not restricted to:
+Cardiovascular Function: Adequate cardiovascular function in the opinion of the Investigator with no clinically significant uncontrolled cardiovascular disease.
+Subject has significant cardiovascular disease, including:
+Uncontrolled cardiovascular history, defined as:
+Clinically significant cardiovascular disease or condition
+Has cardiovascular risk factors
+History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:
+Significant cardiovascular disease including Congestive Heart Failure or poorly controlled hypertension.
+Significant cardiovascular disease, such as
+Predefined cardiovascular disease
+Acute cardiovascular disease in the previous 30 days
+Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1
+Subjects who developed cardiovascular disease within 24 weeks prior to study entry, which is deemed to be clinically significant by the Investigator.
+Has uncontrolled or significant cardiovascular disease
+Known clinically significant cardiovascular disease or condition.
+Have a significant electrocardiogram finding or cardiovascular disease
+No known history of cardiovascular disease
+Currently active, clinically significant cardiovascular disease or a history of myocardial infarction within 6 months prior to inclusion
+Impaired cardiovascular function or clinically significant cardiovascular disease including any of the following: symptomatic congestive heart failure, clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except for atrial fibrillation and paroxysmal supraventricular tachycardia
+Clinically significant, uncontrolled, cardiovascular disease.
+History of clinically-significant cardiovascular disease.
+Any evidence of severe or uncontrolled systemic disease such as clinically significant cardiovascular, pulmonary, hepatic, renal or metabolic disease
+Significant cardiovascular disease
+Uncontrolled or significant cardiovascular disease
+History of cardiovascular illness;
+Significant cardiovascular disease
+Clinically significant cardiovascular disease
+Clinically significant cardiovascular risk.
+Uncontrolled or significant cardiovascular disease
+Clinically significant (i.e., active) cardiovascular disease
+Significant cardiovascular disease.
+Significant cardiovascular disease within 6 months of screening.
+Significant cardiovascular disease within 6 months of screening.
+Significant cardiovascular disease
+Patients with pre-existing history of or known cardiovascular risk
+Uncontrolled or significant cardiovascular disease
+Significant cardiovascular disease
+Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
+Uncontrolled or significant cardiovascular disease
+Significant cardiovascular disease.
+Significant cardiovascular disease
+Clinically significant cardiovascular disease
+History of specific cardiovascular abnormalities;
+Has a history of any of the following cardiovascular conditions within 12 months of randomization:
+Subject has clinically significant cardiovascular disease.
+Clinically significant cardiovascular disease;
+Clinically symptomatic and uncontrolled cardiovascular disease
+Significant cardiovascular disease (including congestive heart failure).
+Significant cardiovascular disease
+Have significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.
+Patients with clinically significant cardiovascular disease.
+History of autoimmune disease, significant pulmonary disease, or significant cardiovascular disease
+Significant active cardiovascular or pulmonary disease including:
+Significant cardiovascular or liver disease
+Significant history of cardiovascular disease
+Patients with clinically significant, uncontrolled cardiovascular disease
+History or presence of clinically relevant cardiovascular abnormalities as per investigator assessment.
+History or evidence of cardiovascular risk including any of the following:
+Significant cardiovascular disease or significant pulmonary disease
+Significant cardiovascular diseases
+Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease
+Serious cardiac or cardiovascular disease or condition
+Have a history or current evidence of uncontrolled cardiovascular disease.
+Significant cardiovascular or pulmonary disease
+Subjects with clinically significant cardiovascular disease.
+Subject has clinically significant cardiovascular disease including:
+Subjects with clinically significant cardiovascular disease. This includes:
+Patient has uncontrolled or significant cardiovascular disease, including:
+Significant cardiovascular disease
+Currently active, clinically significant cardiovascular disease.
+Currently active, clinically significant cardiovascular disease
+Significant cardiovascular disease.
+History or evidence of cardiovascular condition
+Significant cardiovascular disease
+Clinically significant cardiovascular disease;
+Have significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
+Uncontrolled or significant cardiovascular disease, including:
+History of any one or more of the following cardiovascular conditions within the past 6 months:
+Clinically significant cardiovascular disease
+A history of significant renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular or hepatic disease
+Severe cardiovascular or hepatic disease
+Significant cardiovascular disease
+Clinically significant cardiovascular disease
+Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator could affect the subject safety or interfere with the study assessments
+Uncontrolled or significant cardiovascular disease
+Clinically significant (that is, active) cardiovascular disease
+Impaired cardiovascular function or clinically significant cardiovascular diseases
+Cardiovascular conditions as defined in the protocol
+Evidence of current uncontrolled cardiovascular conditions
+Impaired cardiovascular function or clinically significant cardiovascular diseases.
+Impaired cardiovascular function or clinically significant cardiovascular diseases
+History of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease
+History or current evidence of cardiovascular risk.
+Clinical or radiographic evidence of central nervous system metastases or significant cardiovascular disease
+Patients must not have cardiovascular disease risk factors as defined below:
+Clinically relevant cardiovascular abnormalities as judged by the investigator.
+Evidence of current uncontrolled cardiovascular conditions within the past 6 months
+Have significant or active cardiovascular disease
+History of clinically significant cardiovascular disease including.
+Currently active, clinically significant cardiovascular disease
+Known active cardiovascular disease condition as specified in protocol
+Significant cardiovascular disease including CHF, leptomeningeal disease, poorly controlled hypertension, or an MI within 6 months prior to dosing.
+Active cardiovascular disease or significant history thereof.
+Significant cardiovascular disease.
+Clinically significant cardiovascular disease;
+Moderate or severe cardiovascular disease
+DONOR: Significant cardiovascular disease
+History of clinically significant cardiovascular disease including:
+Clinically significant cardiovascular disease at screening including:
+Significant cardiovascular disease including CHF or poorly controlled hypertension.
+Significant cardiovascular disease including CHF or poorly controlled hypertension.
+Significant disease or uncontrolled disease, i.e. cardiovascular renal, hepatic, endocrine, metabolic, neurologic; or other significant disease that would limit the patients ability to participate in the study as determined by the investigator or medical monitor.
+unstable cardiovascular function
+Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, thyroid, or metabolic disease; wound healing disorders; ulcers; or bone fractures)
+Uncontrolled or significant cardiovascular disease
+Uncontrolled or significant cardiovascular disease, including:
+History (within the last 6 months) of significant cardiovascular disease.
+Significant or uncontrolled cardiovascular disease
+Significant cardiovascular disease
+Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)
+History of significant cardiovascular disease, defined as:
+Prior therapy with known risk for cardiovascular complications.
+Clinically significant cardiovascular disease.
+Significant cardiovascular disease
+History of significant cardiovascular disease will be excluded
+Currently active, clinically significant cardiovascular disease or myocardial infarction within 6 months of screening
+Significant history of cardiovascular disease
+Clinically significant cardiovascular impairment
+Significant cardiovascular disease
+History or evidence of cardiovascular risk including any of the following:
+Subject has a significant cardiovascular disease
+Any of the following cardiovascular conditions:
+History or presence of clinically relevant cardiovascular abnormalities
+Significant cardiovascular diseases
+Significant cardiovascular or cerebrovascular disease within 6 months prior to Day 1 of Cycle 1
+A history or evidence of cardiovascular risk including any of the following:
+Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following: symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
+A history or evidence of cardiovascular risk- specific criteria have to be met
+Cardiovascular abnormalities:
+Clinically significant cardiovascular risk
+History of serious cardiovascular disease
+Clinically significant cardiovascular disease
+Significant or uncontrolled cardiovascular disease or bleeding disorder
+Patients with a significant cardiovascular disease or condition, including:
+Ongoing treatment for pre-existing cardiovascular disease
+Evidence of uncontrolled cardiovascular conditions
+Current severe, uncontrolled non-cancer systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) resulting in a life expectancy of < 6 months
+A history or evidence of cardiovascular risk including any of the following
+Patients with a significant cardiovascular disease or condition, including:
+History or current condition of uncontrolled cardiovascular disease
+Uncontrolled or significant cardiovascular disease
+Clinically significant cardiovascular disease including:
+Uncontrolled or significant cardiovascular disease
+Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; bone fractures)
+Uncontrolled hypertension or clinically significant cardiovascular disease
+Current severe, uncontrolled systemic disease (including but not limited to clinically significant cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding the cancer under study
+Patients with the following manifestations of cardiovascular disease are excluded:
+Evidence of current uncontrolled cardiovascular conditions
+Significant cardiovascular impairment, defined as:
+Impaired cardiovascular function or clinically significant cardiovascular diseases
+Patient has uncontrolled or significant cardiovascular disease, including:
+Participants with certain cardiovascular conditions are excluded.
+Participants with any of the following cardiovascular conditions are excluded:
+Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal, or infectious disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
+Uncontrolled or significant cardiovascular disease
+Cardiovascular disease
+Patients with malnutrition, active infection, significant pulmonary disease and cardiovascular disease as determined by the physician as they could impact fatigue
+Unstable cardiovascular disease in the last 6 months
+Uncontrolled or significant cardiovascular disease, including any of the following:
+History of clinically-significant cardiovascular disease
+Significant history of cardiovascular disease
+Any history of cardiovascular, kidney, or liver disease
+Any prior cardiovascular disease
+History of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.
+Patients with known significant active cardiovascular or pulmonary disease at the time of study entry are ineligible
+Significant cardiovascular disease
+Not be undergoing evaluation and workup for active cardiovascular disease; men with treated and stable cardiovascular disease may participate
+Acute major illness (e.g., unstable cardiovascular condition, etc.)
+Acute major illness (e.g., unstable cardiovascular condition, etc.)
+Acute major illness (e.g., infection, unstable cardiovascular condition, etc.)
+Acute major illness (e.g. unstable cardiovascular condition, etc.)
+Significant cardiovascular disease including CHF or poorly controlled hypertension.
+Active, unstable cardiovascular function:
+History of clinically significant cardiovascular disease
+Have any of the following cardiovascular conditions:
+Uncontrolled or significant cardiovascular disease
+Clinically significant cardiac/cardiovascular disease, or pulmonary compromise
+Clinically significant cardiovascular disease including:
+Currently active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first dose